The aim of this study was the survey of cathepsin D determination in a large group of patients enrolled at several centers, under the coordination of the Italian Committee for Quality Control in the Oncological Laboratory. Cathepsin D was measured with the same method-ology, under control of an intra and interlaboratory quality control program, in order to verify the comparability of cathepsin D results from different institutions and to analyze the frequency of cathepsin D positive cases in subgroups of patients stratified according to other prognostic parameters. This retrospective study included 2575 patients with primary breast cancer evaluat-ed in 10 institutions. Cytosol from tumor tissue was the substrate for biochemical cathepsin D, estrogen receptor and progesterone receptor determination, with an interlaboratory quality control survey provided by the E.O.R.T.C. Receptor Group and the Italian Committee for Quality Control in the Oncological Laboratory.
The results of the present study can be summarized as follows:
1) Cathepsin D is independent of menopausal status;
2) In spite of standardization of tissue handling and assay methods, different results may be obtained by different institutions. It is therefore essential that each laboratory calculates its own positive/negative cutoff values prior to any routine clinical use of the parameter. This should be a serious consideration when a multicenter study is planned.
WestleyB., RochefortH.A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell1980; 20: 353–62.
2.
RochefortH., AugereauP., BriozzoP.Structure, function, regulation and clinical significance of 52k pro-cathepsin D secreted by breast cancer cells. Biochimie1988; 70: 943–9.
3.
FreissG., VignonF., RochefortH.Characterization and properties of two MAbs specific for the M dr 52,000 precursor of cathepsin D in human breast cancer cells. Cancer Res1988; 48: 3709–15.
4.
FreissG., VignonF., PauB.A two-site immunoenzymometric assay of 52 kD pro-cathepsin D and its use in human breast diseases. Clin Chem1989; 35(2): 234–7.
5.
GarciaM., LacombeM.J., DuplayH.Immunohistochemical distribution of the 52kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem1987; 27(1–3): 435–45.
6.
CavaillesV., AugereauP., GarciaM., RochefortH.Estrogens and growth factors induce the mRNA of the 52k-pro-cathepsin D secreted by breast cancer cells. Nucleic Acids Res1988; 16: 1903–19.
7.
RochefortH., CaponyF., GarciaM.Estrogen-induced lysosomal protease secreted by breast cancer cells. A role in carcinogenesis? J Cell Biochem1987; 35: 17–29.
8.
VignonF., CaponyF., ChambonM., FreissG., GarciaM., RochefortH.Autocrine growth stimulation of the MCF breast cancer cells by the estrogen-regulated 52K protein. Endocrinology1986; 118: 1537–45.
9.
BriozzoP., MorissetM., CaponyF., RougeotC., RochefortH.In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res1988; 48: 3688–92.
10.
ThorpeS., RochefortH., GarciaM.Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Anticancer Res1989; 49: 6008–14.
11.
SpyratosF., BrouilletJ-P, DefrenneA.Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet1989; 1: 1115–8.
12.
TandonA.K., ClarkG.M., ChamnesG.C., ChirgwinJ.M., McGuireW.L.Cathepsin D and prognosis in breast cancer. N Engl J Med1990; 332: 297–302.
13.
RomainS., MuraccioleX., VaretteI., BressacC., BrandoneH., MartinP.M.La cathepsin-D: un facteur pronostique independant dans la cancer du sein. Bull Cancer1990; 77: 439–47.
14.
GranataG., CoradiniD., CappellettiV., Di FronzoG.Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer1991; 27(8): 970–2.
15.
NamerM., RamaioliA., FontanaX.Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat1991; 19: 85–93.
16.
DuffyM.J., ReillyD., BrouilletJ-P. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem1992; 38(10): 2114–6.
17.
DomagalaW., StrikerG., SzadowskaA., DukowiczA., WeberK., OsbornM.Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol1992; 141: 1003–12.
18.
PujolP., MaudelondeT., DauresJ-P. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer1993; 71: 2006–12.
19.
FoekensJ.A., van PuttenW.L.J., PortengenH.Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol1993; 11: 899–908.
20.
MaudelondeT., KhalafS., GarciaM.Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res1988; 48: 462–6.
21.
BrouilletJ.P., HanslickB., MaudelondeT.Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clin Biochem1991; 24: 491–6.
22.
ParadisoA., MangiaA., CorrealeM.Cytosol cathepsin D content and proliferative activity of human breast cancer. Breast Cancer Res Treat1992; 23: 63–70.
23.
SilvestriniR., VeneroniS., BeniniE., Di FronzoG., DaidoneM.G.p53 and cathepsin D are independent of established prognostic factors in breast cancer. Int J Oncol1992; 1: 507–12.
24.
RavdinP.M., TandonA.K., AllredC.A.Cathepsin D by Western blotting immunohistochemistry: failure to confirm comparisons with prognosis in node-negative breast cancer. J Clin Oncol1994; 12: 467–74.
25.
TanP.E., BenzC.C., DollbaumC.Prognostic value of cathepsin D in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol1994; 5: 329–36.
26.
HenryJ.A., McCarthyA.L., AngusB.Prognostic signficance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer1990; 65: 265–71.
27.
CazinJ.L., GosselinP., BonifaceB., BonifaceM., DemailleA.Expression of pS2 and cathepsin D in breast cancer. Int J Oncol1993; 2: 1081–4.
28.
GionM., DittadiR., LeonA.E.Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicentre study. Eur J Cancer1991; 27(8): 996–1002.
29.
EORTC Breast Cancer Cooperative Group.Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer1980; 16: 1513–5.
30.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem1976; 72: 248–54.
31.
PiffanelliA., PelizzolaD., De BortoliM.Qualitative assurance for steroid receptor assay in human breast cancer: six years experience of the Italian Committee. Tumori1985; 71: 589–95.
32.
BenraadThJ, Geurts-MoespotA., SalaM., PiffanelliA., RossA., FoekensJ.A.Quality control of cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer1992; 28: 72–5.
33.
MittraI., MacRaeK.D.A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology?Eur J Cancer1991; 27(12): 1574–83.
34.
TubianaM., KoscielniS.Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat1991; 18: 125–40.
35.
IngleN.G.Prognostic factors in women with node-negative breast cancer. ASCO Proc1991; 17–22.
36.
FoekensJ.A., PetersH.A., PortengenH., NoordegraafE., BernsEMJJ, KlijnJ.G.M.Cell biological prognostic factors in breast cancer: a review. J Clin Immunoassay1991; 14: 184–95.
37.
GöhringU-J, IngenhorstA., CrombachG., ScharlA.Kathepsin-D-expression im primären mammakarzinom. Pathologe1993; 14: 313–7.
38.
VeneroniS., DaidoneM.G., Di FronzoG.Quantitative immunohistochemical determination of cathepsin D and its relation with other variables. Breast Cancer Res Treat1993; 26: 7–13.
